- BioNTech’s Dr. Ugur Sahin topped Fierce Pharma‘s 2024 list with $287 million, while Pfizer’s Albert Bourla ($24.6 million) and Eli Lilly’s David Ricks ($29.2 million) ranked among the highest-paid, reflecting booming drug sales (e.g., weight-loss drugs, COVID-19 vaccines).
- Executives’ multimillion-dollar payouts contrast sharply with soaring prescription costs, eroding public trust as patients struggle to afford medications like insulin.
- Major firms (Merck, Bristol Myers Squibb, AstraZeneca, J&J) are suing to block Medicare price negotiations, while industry lobbying fights to maintain high drug prices despite evidence of greater spending on stock buybacks than R&D.
- Executives at Pfizer, Moderna and J&J cashed out $250 million in stocks post-Operation Warp Speed, while Moderna’s CEO earned $392 million in 2023 despite missing the 2024 list.
- Critics highlight a rigged system where executive bonuses and corporate profits take priority over affordable healthcare, widening the gap between boardroom gains and patient hardships.
(Natural News)—As Big Pharma executives continue to amass staggering fortunes, patients face soaring prescription costs and dwindling trust in an industry that profits from lifesaving medicines.
Fierce Pharma released its Top 10 highest-paid pharmaceutical executives list for 2024 on Monday, June 16. BioNTech’s Dr. Ugur Sahin topped the list at $287 million – nearly 10 times more than his closest competitor. Eli Lilly’s David Ricks, who landed on No. 2, secured $29.2 million amid booming sales of weight-loss drugs Zepbound and Mounjaro.
Pfizer CEO Albert Bourla landed on No. 3 in the list, with his earnings rebounding to $24.6 million after the Wuhan coronavirus (COVID-19) slump. AstraZeneca’s Pascal Soriot, who pocketed $22.9 million despite investor backlash over bonus hikes, was in ninth place.
The eye-popping figures compiled by Fierce Pharma revealed an elite class of executives whose paychecks dwarf the average American’s lifetime earnings. They also underscored a widening chasm between corporate profits and public health.
While Sahin’s windfall came from cashing out stock options tied to BioNTech’s pandemic-era mRNA vaccine success, Moderna’s Stephane Bancel was conspicuously absent from the list due to his company’s smaller market cap. He remains formidable despite his absence on the 2024 list after raking in $392 million in 2023. (Related: GREED PARADE: Moderna plans to sell COVID-19 vaccine for up to $130 per dose – more than 8 times its initial price of $15.25 per dose.)
Meanwhile, Johnson & Johnson’s Joaquin Duato saw his pay drop 14 percent to $24.6 million – putting him on No. 5 in the list. J&J remains embroiled in costly talc litigation and lawsuits over its discontinued COVID-19 vaccine linked to fatal blood clots.
Big Pharma prioritizes PROFITS over people
Critics argue these payouts reflect a system rigged in favor of executives, even as drugmakers lobby aggressively against Medicare price negotiations. Merck and Bristol Myers Squibb, whose CEOs earned $23.2 million (No. 7 on the list) and $18.8 million (No. 10) respectively, are among those suing the government to block lower drug costs.
AstraZeneca and J&J have joined the legal battle, while the Pharmaceutical Research and Manufacturers of America – the industry’s lobbying arm – fights to preserve pricing power. Meanwhile, research shows top firms spend more on stock buybacks and dividends than on R&D, debunking claims that high prices fund innovation.
The trend isn’t new. During the pandemic, executives at Pfizer, Moderna and J&J cashed out $250 million in stocks within six months of Operation Warp Speed, as per watchdog group Accountable.US. Bourla’s net worth, estimated at $35.6 million, places him in the wealthiest one percent of Americans – a stark contrast to the millions rationing insulin or skipping doses due to cost.
As the pharmaceutical industry braces for more scrutiny, one question lingers. When will the pursuit of profit align with the promise of affordable healthcare? For now, the gap between boardroom bonuses and patients’ bills has never been wider.
Head over to BigPharmaNews.com for more similar stories. Watch AstraZeneca CEO Pascal Soirot agreeing with U.S. President Donald Trump’s order to lower drug prices in this Fox Business interview.
This video is from the NewsClips channel on Brighteon.com.
More related stories:
- Coronavirus pandemic creates 9 new Big Pharma billionaires.
- Pfizer CEO Albert Bourla now HIGHEST PAID pharma executive in the world.
- Heads of vaccine makers Moderna, BioNTech included in list of COVID-19 billionaires.
Sources include:
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.
